Journal
CLINICAL JOURNAL OF PAIN
Volume 23, Issue 8, Pages 702-706Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/AJP.0b013e31814b1afa
Keywords
intravenous lidocaine; systemic lidocaine; lidocaine neuropathic pain; chronic pain; palliative care; lidocaine infusion; cohort study; logistic regression; aging; prediction
Categories
Funding
- NIDA NIH HHS [K24 DA029262] Funding Source: Medline
- NINDS NIH HHS [R01 NS053961-01, R01 NS053961, R01NS053961-01] Funding Source: Medline
Ask authors/readers for more resources
Objectives: The proportion of chronic pain patients with suspected neuropathic pain who will have clinically meaningful pain relief with intravenous (IV) lidocaine and the clinical characteristics that identify these patients have not been described previously. Methods: We conducted a cohort study of 99 patients who underwent IV lidocaine infusions for suspected neuropathic pain. An 11-point Numerical Rating Score (NRS) of pain intensity was recorded at the beginning and end of each infusion. A predefined literature-based criteria for clinically meaningful reductions in pain score was used to classify patients as responders or nonresponders. Multivariate logistic regression was used to determine clinical variables that predicted an increased likelihood of being a lidocaine responder. Results: The mean reduction in NRS during lidocaine infusions was 2.34 (95% confidence interval 2.83-1.85, P < 0.001). Forty-two percent of patients (95% confidence interval 32.5%-52.8%) had NRS reductions of 30% or greater and met the predefined criteria as lidocaine responders. Univariate and multivariate analyses indicated that advancing age and pain severity significantly increased the odds of being a lidocaine responder. Controlled for all other factors, each decade of advancing age increased the odds of being a lidocaine responder by 36%. Each 1-point increase, on an 11-point scale of baseline pain severity, increased the odds of being a lidocaine responder by 29%. Discussion: IV lidocaine effectively reduces pain in a minority of patients suspected of having neuropathic pain. Pain severity and patient age can be used to target therapy to those most likely to respond.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available